ロード中...
How I treat relapsed or refractory AML
Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented challenges for hematologists for decades. Despite numerous clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of ∼10%. Allogeneic hematopoietic cell transplantation at the time of...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7453152/ https://ncbi.nlm.nih.gov/pubmed/32518943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001982 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|